Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million

Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
On October 1, Celldex Therapeutics, Inc. announced the successful completion of its acquisition of CuraGen Corporation. The purchase price for CuraGen was approximately $93.5 million and, as a result of the merger, CuraGen has become a wholly owned subsidiary of Celldex. The acquisition adds a portfolio of oncology-focused, fully-owned antibodies to Celldex's Precision Targeted Immunotherapy Platform.

WilmerHale represented CuraGen in this transaction. The WilmerHale team included Lara Mataac and Ravi Faiia from the Corporate Group, and Kimberly Wethly from the Tax Group. William Schmidt advised on employee benefits, Sally Byrne advised on licensing and Michael Twomey advised on patent matters.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel